Scarica l'app Stockscreener
1.1693
2.39%
0.0273
Precedente Chiudi:
$1.142
Aprire:
$1.17
Volume 24 ore:
5,611
Relative Volume:
0.07
Capitalizzazione di mercato:
$27.66M
Reddito:
-
Utile/perdita netta:
$-22.29M
Rapporto P/E:
-0.9909
EPS:
-1.18
Flusso di cassa netto:
$-17.12M
1 W Prestazione:
-1.74%
1M Prestazione:
-7.20%
6M Prestazione:
-0.91%
1 anno Prestazione:
-15.88%
Intervallo 1D:
$1.1693
$1.1777
Intervallo di 1 settimana:
$1.13
$1.32
Portata 52W:
$0.8101
$1.76
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Nome
Enlivex Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ENLV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.1693 | 27.90M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.53 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.35 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.50 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.70 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.62 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-02 | Reiterato | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Borsa (ENLV) Ultime notizie
Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital - Defense World
Enlivex Therapeutics Ltd. Stock Analysis and ForecastFree Stock Market Query - PrintWeekIndia
What drives Enlivex Therapeutics Ltd. stock priceFree Capital Growth Strategies - PrintWeekIndia
Is Enlivex Therapeutics Ltd. a good long term investmentExceptional profit velocity - Autocar Professional
What analysts say about Enlivex Therapeutics Ltd. stockExceptional market positioning - jammulinksnews.com
Enlivex Therapeutics (ENLV) Receives Continued 'Buy' Rating from Analyst | ENLV Stock News - GuruFocus
why enlivex therapeutics ltd. stock attracts strong analyst attentionLow Risk Entry Points - Newser
Why Enlivex Therapeutics Ltd. stock attracts strong analyst attentionReal Trader Insights - beatles.ru
How Enlivex Therapeutics Ltd. stock performs during market volatilityPrecision Entry Strategy - Newser
What makes Enlivex Therapeutics Ltd. stock price move sharplyReturn Maximized Portfolio Strategy - Newser
Sepsis Market Growth to Accelerate in Forecast Period - openPR.com
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle
Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel
Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus
Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus
Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times
Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan
Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal
Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times
Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud
Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World
Enlivex Therapeutics Ltd Azioni (ENLV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.74%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):